Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
P27(Kip1) Loss does not predict survival in patients with advanced gastriccarcinoma
Autore:
Feakins, RM; Mulcahy, HE; Quaglia, A; Jawhari, A; Zhang, Z; Patchett, SE;
Indirizzi:
Univ London, Univ London Queen Mary & Westfield Coll, Royal London Hosp, Dept Histopathol & Morbid Anat, London E1 4NS, England Univ London London England E1 4NS & Morbid Anat, London E1 4NS, England Univ London, Univ London Queen Mary & Westfield Coll, Digest Dis Res Ctr, London E1 4NS, England Univ London London England E1 4NS st Dis Res Ctr, London E1 4NS, England Univ London, Royal Free Hosp, Royal Free & Univ Coll Med Sch, Dept Histopathol, London, England Univ London London England l Med Sch, Dept Histopathol, London, England Beaumont Hosp, Dept Gastroenterol, Dublin 9, Ireland Beaumont Hosp Dublin Ireland 9 sp, Dept Gastroenterol, Dublin 9, Ireland
Titolo Testata:
CANCER
fascicolo: 8, volume: 89, anno: 2000,
pagine: 1684 - 1691
SICI:
0008-543X(20001015)89:8<1684:PLDNPS>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEPENDENT KINASE INHIBITOR; CELL-CYCLE; PROGNOSTIC IMPLICATIONS; HELICOBACTER-PYLORI; EXPRESSION; CANCER; P27; STAGE; ADENOCARCINOMA; PROTEIN;
Keywords:
p27(Kip1) expression; gastric adenocarcinoma; prognosis; pathogenesis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Feakins, RM Univ London, Univ London Queen Mary & Westfield Coll, Royal London Hosp, Dept Histopathol & Morbid Anat, London E1 4NS, England Univ London London England E1 4NS at, London E1 4NS, England
Citazione:
R.M. Feakins et al., "P27(Kip1) Loss does not predict survival in patients with advanced gastriccarcinoma", CANCER, 89(8), 2000, pp. 1684-1691

Abstract

BACKGROUND, p27(Kipl) is a cyclin-dependent kinase inhibitor whose loss isassociated with disease progression and an unfavorable outcome in several malignancies. The authors studied its expression in a consecutive series ofresected gastric carcinomas. METHODS. Expression of p27(Kipl) in 71 advanced gastric carcinomas and 10 lymph nodes containing metastases was determined using an avidin-biotin-peroxidase immunohistochemical method. The relations between p27(Kipl) expression and pathologic features, patient characteristics, and survival were analyzed. RESULTS. p27(Kipl) levels in gastric carcinomas ranged from 0.63-82.97% (median, 23.10%; mean, 27.99%). There was no association found between p27(Kipl) expression and patient gender (P = 0.21), patient age (P = 0.13), tumorstage (P = 0.17), tumor grade (P = 0.22), or histologic type (P = 0.72). Univariate analysis showed that long term survival was related to stage (P <0.0001) and grade (P = 0.03). However, tumors with p27(Kipl) levels above and below the median value were associated with a similar outcome, regardless of whether all cases (P = 0.19) or those without metastatic disease (P =0.50) or those with residual or metastatic disease (P = 0.92) were included. When entered into a multivariate analysis, stage (P < 0.0001) and grade (P = 0.05), but not p27(Kipl) levels (P = 0.16), were found to be related to patient outcome. In lymph node metastases, p27(Kipl) expression (median, 16.5%) was similar to that found in the corresponding primary lesion (median, 30.9%). CONCLUSIONS. p27(Kipl) may play a role in the pathogenesis and progressionof gastric carcinoma, but its expression is unlikely to be useful as a prognostic indicator, at least in European patients with advanced disease. Cancer 2000;89: 1684-91. (C) 2000 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 14:39:55